Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Desreportption
According to report, the rapid development of China's economy in the past 30 years has brought about changes in people's lifestyles, for example, the reduction in exercise and the rising intake of calories, which increases the incidence of diabetes. It is estimated that by the end of 2017, the number of diabetic patients in China had exceeded 100 million. For patients with Type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with Type 2 diabetes eventually become insulin dependent.
With the increasing number of diabetic patients, the market size of diabetes drugs in China is expanding. Third-generation insulin such as Insulin Glargine, Insulin Aspart and Insulin Lispro take up a large market share.
Recombinant Lispro Insulin is a new-type insulin analogue that takes effect more quickly, lasts for a shorter period and is more in line with the insulin secretion curve during physiological meals. Preparations Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) can all better control blood sugar and reduce hypoglycemia. Recombinant Lispro Insulin was developed by Lilly. Lilly’s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) (trade name: Humalog Mix25), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50) were approved by the FDA for the treatment of diabetes between Apr. 1996 and Dec.1999, and launched in China in 2005, 2010 and 2008 respectively. By the end of 2018, in addition to Lilly’s Humalog, the only Recombinant Lispro Insulin products in China are domestic manufacturer Gan & Lee Pharmaceuticals' Recombinant Lispro Insulin Injection and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) that were launched in 2006 and 2014 respectively.
According to report, Recombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY 243 million in 2017. The only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals. By sales value, the market share of Lilly's Recombinant Lispro Insulin exceeded 98% in 2017 but is declining slowly. Optimistic about China's Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin. For example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R). It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.
It is expected that as the number of diabetic patients continues to increase, China’s Recombinant Lispro Insulin market will still have some growth potential.
Topics Covered:
- Situation of diabetes and overview of the antidiabetic drug market in China
- Market size of Recombinant Lispro Insulin in China
- Major Recombinant Lispro Insulin manufacturers in China
- Prices of Recombinant Lispro Insulin in China
- Major factors affecting the development of China's Recombinant Lispro Insulin market
- Prospect of China's Recombinant Lispro Insulin market
According to report, the rapid development of China's economy in the past 30 years has brought about changes in people's lifestyles, for example, the reduction in exercise and the rising intake of calories, which increases the incidence of diabetes. It is estimated that by the end of 2017, the number of diabetic patients in China had exceeded 100 million. For patients with Type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with Type 2 diabetes eventually become insulin dependent.
With the increasing number of diabetic patients, the market size of diabetes drugs in China is expanding. Third-generation insulin such as Insulin Glargine, Insulin Aspart and Insulin Lispro take up a large market share.
Recombinant Lispro Insulin is a new-type insulin analogue that takes effect more quickly, lasts for a shorter period and is more in line with the insulin secretion curve during physiological meals. Preparations Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) can all better control blood sugar and reduce hypoglycemia. Recombinant Lispro Insulin was developed by Lilly. Lilly’s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) (trade name: Humalog Mix25), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50) were approved by the FDA for the treatment of diabetes between Apr. 1996 and Dec.1999, and launched in China in 2005, 2010 and 2008 respectively. By the end of 2018, in addition to Lilly’s Humalog, the only Recombinant Lispro Insulin products in China are domestic manufacturer Gan & Lee Pharmaceuticals' Recombinant Lispro Insulin Injection and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) that were launched in 2006 and 2014 respectively.
According to report, Recombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY 243 million in 2017. The only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals. By sales value, the market share of Lilly's Recombinant Lispro Insulin exceeded 98% in 2017 but is declining slowly. Optimistic about China's Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin. For example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R). It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.
It is expected that as the number of diabetic patients continues to increase, China’s Recombinant Lispro Insulin market will still have some growth potential.
Topics Covered:
- Situation of diabetes and overview of the antidiabetic drug market in China
- Market size of Recombinant Lispro Insulin in China
- Major Recombinant Lispro Insulin manufacturers in China
- Prices of Recombinant Lispro Insulin in China
- Major factors affecting the development of China's Recombinant Lispro Insulin market
- Prospect of China's Recombinant Lispro Insulin market
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
